Abstract:Background: Despite the potential for tumor-specific T cells to mediate durable complete responses, even in advanced disease, no CAR-T cell treatment is currently approved for use against any solid cancers [1–3]. While a large majority of solid cancers express tumor-associated antigens (TAAs) that are vulnerable to CAR T cell recognition, in nearly all cases TAAs are present in healthy tissues [4]. Since CAR T cells cannot differentiate between cancer and normal cells, CAR T cell recognition of TAAs on healthy tissues provokes dose-limiting 'on-target off-tumor' toxicities at sites of endogenous expression, most commonly the lungs [5–8]. Metastatic patterns of solid cancer are heterogenous, and in some cases lethal disease is limited to a single organ throughout a patient's entire disease course – i.e. oligometastasis. For example, the liver is the sole site of metastasis in approximately 20,000 colorectal cancer deaths per year in the United States and the most common site of visceral metastasis from solid cancer overall [9–11]. We sought to capitalize on the oligometastatic biology of some cancers by genetically encoding CAR-T cells to restrict their activity to the cancer involved-organ while limiting CAR-T cell trafficking and associated toxicity to non-cancer sites. Methods: We develop two immunocompetent murine models of CAR T cell transfer targeting TAAs abundant in metastatic colorectal cancer and pancreatic cancer (EpCAM and CEA). Conventional TAA-specific CAR T cells affected tumor shrinkage but also infiltrated and damaged non-cancerous organs that expressed the TAA (lung, pancreas, & colon) [12]. The respiratory system was the site of greatest pathology in both models, with massive CAR T cell accumulation and tissue destruction, resulting in dose-limiting lethality. To mitigate off-tumor toxicity, we developed a multiparameter genetically encoded program that leverages endogenous chemokine and tissue resident systems to imbue CAR-T cells with liver tropism and enhanced functionality (Figure 1). Results: Liver-directed programming of CAR T cells in both CEA and EpCAM CAR models resulted in highly preferential trafficking of CAR T cells to liver tumors and limited CAR T cell trafficking and toxicity in non-cancerous tissues that share expression of the tumor associated antigen. Conclusions: Organ-directed targeting of TAA specific CAR-T cells is a promising approach to treat oligo-metastatic disease while avoiding off-tumor toxicities. Based on these results we are preparing to initiate phase 1b clinical (3+3) trial using liver-directed CEA specific CAR T cells in patients with colorectal liver metastasis. Citation Format: Alexandra Bartlett, Robert MD Eil. A novel approach and model to limit cytokine release syndrome and off-tumor toxicity of synthetically enhanced CEA CAR-T cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B050.

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects

Abstract B050: A novel approach and model to limit cytokine release syndrome and off-tumor toxicity of synthetically enhanced CEA CAR-T cells

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

Abstract LB071: Weaponizing CAR T-cells to attack PD-L1 presenting cells in solid tumors

Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models

Abstract 62: Intra-tumor persistence of activated anti-mesothelin hYP218 CAR T cells is associated with increased efficacy in gastric and colorectal cancers

Abstract B035: Enhanced tumor infiltration and functionality of anti-GPC3 CAR-T cells in hepatocellular carcinoma through locoregional administration

Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model

Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis

Abstract 6335: Armoring CAR-T therapy with PD-1 blockade: a powerful strategy for enhancing anti-tumor effects in pancreatic cancer

Challenges of Anti-Mesothelin CAR-T-Cell Therapy

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy

Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy